Dramatic results showing that radioimmunotherapy with Zevalin prolongs progression-free survival by 2 years come just days after cuts in reimbursement for this therapy were announced in the United States. Medscape Medical News
Identification of sporadic mismatch repair (MMR)-defective tumors is central to improved prognostication. Can clinicopathologic criteria be used to select sporadic tumors for evaluation of MMR status? American Journal of Clinical Pathology
Tumors positive for human papillomavirus (HPV) have a better response to therapy, leading to significantly better survival than HPV-negative cancers. Medscape Medical News